首頁 > 市場調查報告書 > 醫療設備

體外診斷孤兒藥

市場調查報告書

商品編碼

2126405

罕見疾病診斷市場－策略分析與預測（2026-2035）

Rare Disease Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月10日 | 出版商:

Knowledge Sourcing Intelligence | 英文 177 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計罕見疾病診斷市場將從 2026 年的 36 億美元成長到 2035 年的 52.6 億美元，複合年成長率為 4.3%。

罕見疾病診斷市場正經歷重大變革，其驅動力包括：向全面基因測序的模式轉移、國家級基因組醫學計畫的擴展，以及精準醫療在罕見疾病管理中日益增強的融合。這一市場演變的特點在於，人們逐漸認知到數千種罕見疾病是由基因引起的，而早期分子診斷正在支持個人化治療方案的製定、生育諮詢、新生兒篩檢的擴展以及參與疾病特異性臨床試驗。次世代定序、人工智慧和多組體學平台的融合，使得罕見疾病的辨識速度更快、準確度更高、覆蓋率更廣。隨著疾病修正治療的日益普及，精準基因診斷的臨床價值不斷提升，基因組診斷正被整合到醫療保健系統的常規病患管理中。國家級基因組醫學計畫正在擴展實驗室基礎設施、基因組資料庫和臨床醫生培訓舉措，以將基因組檢測融入常規醫療服務。市場正在對擴充性的定序平台、自動化測試工作流程和人工智慧驅動的分析軟體進行大量投資，罕見疾病診斷正日益成為精準醫療和孤兒藥開發的關鍵促進因素。

市場促進因素

次世代定序(NGS) 的廣泛應用是罕見疾病診斷市場的主要驅動力。 NGS 能夠同時評估數千個與遺傳疾病相關的基因，是現代罕見疾病診斷的基礎。隨著診斷複雜性的不斷增加，臨床檢查室正從單一基因檢測轉向全面的基因組檢測。這種轉變減少了診斷延遲，同時提高了對遺傳異質性疾病致病突變的檢測準確性。因此，診斷設備製造商持續投資於高通量定序平台、自動化工作流程和整合生物資訊解決方案，以提高檢查室效率和臨床擴充性，從而推動罕見疾病診斷應用的持續成長。精準醫療和孤兒藥研發的擴展，透過增加對分子層級確認的需求，進一步加速了市場成長。精準醫療依賴準確的分子診斷，因為確認致病基因突變對於確定治療合格至關重要。隨著標靶治療不斷擴展到神經肌肉疾病、代謝性疾病、血液疾病和神經系統疾病等罕見疾病領域，製藥公司正在臨床研發的早期階段引入基因組檢測。這種整合正在推動對能夠識別目標患者群體的已驗證檢驗檢測方法的需求。因此，診斷公司正在加強與生物技術公司的合作，以支持生物標記的發現、伴隨診斷的開發以及分散式臨床試驗的受試者招募。各國的基因組醫學計畫正在擴展臨床檢測基礎設施，並推動先進診斷平台的應用。各國政府已將基因組醫學視為一項重要的醫療保健職能，因為早期診斷能夠改善患者預後並減少低效率的醫療資源利用。國家定序計畫正在擴展檢查室基礎設施、基因組資料庫，並開展臨床醫生培訓舉措，以將基因組檢測融入日常診療實踐。這些投資正在提高定序設備的可近性，並增加對定序設備、檢查室自動化、數據分析軟體和認證診斷服務的需求。

市場限制因素

全面基因測序和先進生物資訊學的高成本阻礙了資源匱乏的醫療系統常規應用這些技術。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。不一致的保險報銷政策限制了許多疑似罕見疾病患者獲得檢測的機會。不同地區的保險覆蓋範圍差異給診斷機構帶來不確定性，並限制了患者的就醫途徑。許多超罕見突變缺乏臨床證據，導致突變解讀複雜化，增加了意義不明突變的比例，並延長了確診所需的時間。缺乏可靠的證據給一致的解讀帶來了挑戰。基因組數據基礎設施的碎片化和不同的檢測報告標準限制了醫療系統之間的互通性。此外，不同司法管轄區法規的複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
罕見疾病概述
罕見疾病診斷方法的變化
罕見疾病診斷生態系統
主要市場趨勢
實際成果值市場規模分析
市場預測
疾病負擔與未滿足的診斷需求
疾病盛行率分析
已確診患者族群的分析
對所進行的診斷測試數量進行分析
對患者診斷進展的分析
目前診斷流程

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新型診斷技術
基因組學和多組體學領域的創新
生物標記發現趨勢
對與罕見疾病診斷相關的臨床試驗進行分析
罕見疾病診斷技術流程分析
人工智慧在罕見疾病診斷的應用
與數位健康整合
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章：全球罕見疾病診斷市場：展望分析

分析：按技術平台
分析：按診斷方式
分析：依檢體類型
分析：透過臨床應用
分析：透過測試方法
分析：按最終用戶

第9章：全球罕見疾病診斷市場：細分市場分析

透過技術
- 次世代定序（NGS）
- 全基因測序（WGS）
- 全EXOME定序（WES）
- 聚合酵素鏈鎖反應（PCR）
- 免疫測量
- 其他
依疾病類型
- 罕見遺傳疾病
- 罕見神經系統疾病
- 罕見代謝性疾病
- 罕見血液疾病
- 罕見免疫疾病
- 罕見癌症
- 罕見心血管疾病
- 其他
依檢體類型
- 血
- 組織
- 唾液/口腔黏膜拭子
- 尿
- 其他
依產品類型
- 裝置
- 試劑和耗材
- 軟體診斷服務
最終用戶
- 醫院
- 診斷檢查室
- 專業和參考檢測機構
- 其他

第10章：全球罕見疾病診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：全球罕見疾病診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Illumina, Inc.
Revvity, Inc.
QIAGEN NV
Thermo Fisher Scientific Inc.
Eurofins Scientific SE
Myriad Genetics, Inc.
Centogene NV
Guardant Health, Inc.
BGI Genomics Co., Ltd.

第14章：全球罕見疾病診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009117

The Rare Disease Diagnostics Market is expected to grow at a CAGR of 4.3% from a market value of USD 3.60 billion in 2026 to USD 5.26 billion in 2035.

The rare disease diagnostics market is undergoing significant transformation driven by the paradigm shift toward comprehensive genomic sequencing, the expansion of national genomic medicine programs, and the growing integration of precision medicine into rare disease management. The market's evolution is characterized by the recognition that thousands of rare diseases are genetically driven, and earlier molecular diagnosis supports personalized treatment planning, reproductive counseling, newborn screening expansion, and enrollment into disease-specific clinical trials. The convergence of next-generation sequencing, artificial intelligence, and multi-omics platforms is enabling faster, more accurate, and increasingly comprehensive rare disease identification. Healthcare systems are integrating genomic diagnostics into routine patient management as the growing availability of disease-modifying therapies increases the clinical value of accurate genetic diagnosis. National genomic medicine programs are expanding laboratory infrastructure, genomic databases, and clinician training initiatives to integrate genomic testing into routine healthcare. The market is witnessing significant investment in scalable sequencing platforms, automated laboratory workflows, and AI-enabled interpretation software, positioning rare disease diagnostics as a critical enabler of precision medicine and orphan drug development.

Market Drivers

The growing adoption of next-generation sequencing represents the primary driver for the rare disease diagnostics market. NGS serves as the foundation of modern rare disease diagnosis because it simultaneously evaluates thousands of genes associated with inherited disorders. Clinical laboratories are increasingly replacing sequential single-gene testing with comprehensive genomic panels as diagnostic complexity continues rising. This transition reduces diagnostic delays while improving detection of pathogenic variants across genetically heterogeneous diseases. Diagnostic manufacturers therefore continue investing in higher-throughput sequencing platforms, automated workflows, and integrated bioinformatics solutions that improve laboratory efficiency and clinical scalability, resulting in sustained growth in rare disease diagnostic utilization. The expanding precision medicine and orphan drug development is further accelerating market growth through increased demand for molecular confirmation. Precision medicine depends on accurate molecular diagnosis because therapeutic eligibility increasingly requires confirmation of disease-causing genetic variants. Pharmaceutical sponsors are incorporating genomic testing earlier in clinical development as targeted therapies continue expanding across neuromuscular, metabolic, hematological, and neurological rare diseases. This integration increases demand for validated diagnostic assays capable of identifying appropriate patient populations. Diagnostic companies consequently continue strengthening collaborations with biotechnology firms to support biomarker discovery, companion diagnostic development, and decentralized clinical trial recruitment. National genomic medicine programs are expanding clinical testing infrastructure and driving adoption of advanced diagnostic platforms. Governments recognize genomic medicine as an essential healthcare capability because earlier diagnosis improves patient outcomes while reducing inefficient healthcare utilization. National sequencing programs are expanding laboratory infrastructure, genomic databases, and clinician training initiatives to integrate genomic testing into routine healthcare. These investments improve accessibility while increasing demand for sequencing instruments, laboratory automation, data interpretation software, and accredited diagnostic services.

Market Restraints

High cost of comprehensive genomic sequencing and advanced bioinformatics limits routine adoption in resource-constrained healthcare systems. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Inconsistent reimbursement policies reduce testing accessibility for many patients with suspected rare diseases. Coverage differences across regions create uncertainty for diagnostic providers and limit patient access. Limited availability of clinical evidence for numerous ultra-rare variants complicates variant interpretation, increasing the proportion of variants of uncertain significance and extending the time required for definitive diagnosis. The lack of robust evidence creates challenges for consistent interpretation. Fragmented genomic data infrastructure and differences in laboratory reporting standards restrict interoperability across healthcare systems. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Product Insights

The technology landscape is characterized by the growing importance of comprehensive genomic sequencing, multi-omics integration, and AI-enabled interpretation. NGS serves as the foundation of modern rare disease diagnosis because it simultaneously evaluates thousands of genes associated with inherited disorders. Clinical laboratories are increasingly replacing sequential single-gene testing with comprehensive genomic panels as diagnostic complexity continues rising. WGS and WES provide comprehensive genomic characterization. PCR remains important for targeted mutation detection. Immunoassays continue supporting biochemical and protein biomarker assessment. The segment analysis reveals that rare genetic disorders account for a substantial share of diagnostic demand because most rare diseases originate from inherited pathogenic variants that require molecular confirmation before clinical intervention. Healthcare providers are increasingly adopting comprehensive sequencing panels, WES, and WGS as patients continue presenting with heterogeneous clinical manifestations. Rare neurological, metabolic, hematological, immunological, oncological, and cardiovascular disorders represent significant and growing segments. Reagents and consumables represent the recurring demand component because every molecular diagnostic workflow depends on sequencing kits, library preparation reagents, extraction chemicals, quality control materials, and specialized assay consumables. Testing volumes are increasing across hospitals and reference laboratories as genomic medicine continues moving into routine clinical care. Diagnostic laboratories constitute the primary end users because they possess specialized sequencing infrastructure, accredited quality management systems, and multidisciplinary expertise required for complex genomic interpretation. The integration of AI is becoming increasingly important because AI platforms are improving variant prioritization by integrating genomic evidence, published literature, functional databases, and phenotype information into automated analytical workflows.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and sequencing companies alongside specialized rare disease, genomic, and precision medicine providers. Roche maintains a leading position by combining molecular diagnostics, sequencing technologies, and pharmaceutical expertise within an integrated precision medicine strategy, continuing to expand genomic testing capabilities through Roche Diagnostics while strengthening biomarker-driven therapeutic development across oncology and inherited diseases. Illumina remains the global leader in NGS by providing scalable sequencing instruments, consumables, and bioinformatics solutions widely adopted in clinical genomics, continuing to improve sequencing accuracy while expanding software platforms that simplify genomic interpretation for clinical laboratories. Revvity has established a strong presence in newborn screening and inherited disease diagnostics through integrated laboratory technologies and genomic testing solutions, continuing to expand molecular testing capabilities. QIAGEN differentiates itself through sample preparation technologies, molecular assays, digital PCR platforms, and bioinformatics solutions supporting clinical genomics, with laboratories increasingly adopting its integrated workflow. Thermo Fisher Scientific offers one of the industry's broadest molecular diagnostics portfolios, integrating sequencing instruments, PCR technologies, reagents, laboratory software, and clinical research services. Centogene specializes exclusively in rare disease diagnostics and therefore differentiates itself through deep expertise in genomic interpretation, biodata integration, and global patient databases. Companies are pursuing product portfolio expansion through innovation in NGS platforms, multi-omics solutions, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision medicine. Recent key developments include Broad Institute, Boston Children's Hospital, and The Jackson Laboratory collaboration launching the Center for Therapeutic Genetics as a non-profit effort to develop genetic medicines for rare and ultra-rare diseases. Anthropic opened applications for its AI for Science rare disease program, offering up to $50,000 in Claude API credits per team to support rare genetic disease research. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The rare disease diagnostics market is positioned for sustained growth driven by the convergence of genomic sequencing adoption, orphan drug development, and national genomic initiatives. The transition from sequential single-gene testing toward comprehensive genomic sequencing represents a fundamental shift in rare disease management. While challenges related to high costs, reimbursement variability, and interpretation complexity persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with rare disease diagnostics evolving into a strategic enabler of precision medicine, supporting earlier diagnosis, therapeutic selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Rare Disease Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Rare Disease Overview
3.3 Evolution of Rare Disease Diagnostics
3.4 Diagnostic Ecosystem for Rare Diseases
3.5 Key Market Trends
3.6 Historical Market Size Analysis (2021-2025)
3.7 Market Forecast (2026-2035)
3.8 Disease Burden & Unmet Diagnostic Needs
3.9 Disease Prevalence Analysis
3.10 Diagnosed Patient Population Analysis
3.11 Diagnostic Testing Volume Analysis
3.12 Patient Diagnostic Journey Analysis
3.13 Current Diagnostic Pathways

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Genomic & Multi-Omics Innovation
6.3 Biomarker Discovery Trends
6.4 Clinical Trial Analysis for Rare Disease Diagnostics
6.5 Pipeline Analysis of Rare Disease Diagnostic Technologies
6.6 AI Integration in Rare Disease Diagnosis
6.7 Digital Health Integration
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Rare Disease Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Diagnostic Modality
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by End User

9. Global Rare Disease Diagnostics Market Segment Analysis (2021-2035)

9.1 By Technology
- 9.1.1 Next-Generation Sequencing (NGS)
- 9.1.2 Whole Genome Sequencing (WGS)
- 9.1.3 Whole Exome Sequencing (WES)
- 9.1.4 Polymerase Chain Reaction (PCR)
- 9.1.5 Immunoassays
- 9.1.6 Others
9.2 By Disease Type
- 9.2.1 Rare Genetic Disorders
- 9.2.2 Rare Neurological Disorders
- 9.2.3 Rare Metabolic Disorders
- 9.2.4 Rare Hematological Disorders
- 9.2.5 Rare Immunological Disorders
- 9.2.6 Rare Oncological Disorders
- 9.2.7 Rare Cardiovascular Disorders
- 9.2.8 Others
9.3 By Sample Type
- 9.3.1 Blood
- 9.3.2 Tissue
- 9.3.3 Saliva/Buccal Swab
- 9.3.4 Urine
- 9.3.5 Others
9.4 By Product Type
- 9.4.1 Instruments
- 9.4.2 Reagents & Consumables
- 9.4.3 Software & Diagnostic Services
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Diagnostic Laboratories
- 9.5.3 Specialty & Reference Laboratories
- 9.5.4 Others

10. Global Rare Disease Diagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Rare Disease Diagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Illumina, Inc.
13.3 Revvity, Inc.
13.4 QIAGEN N.V.
13.5 Thermo Fisher Scientific Inc.
13.6 Eurofins Scientific SE
13.7 Myriad Genetics, Inc.
13.8 Centogene N.V.
13.9 Guardant Health, Inc.
13.10 BGI Genomics Co., Ltd.